Honest, paywall-free news is rare. Please support our boldly independent journalism with a donation of any size.
Image Credit: Gilead Sciences
As the number of confirmed COVID-19 cases worldwide approaches 4 million and the pandemic could be with us for months or years, we look at who can access drugs like remdesivir, being developed by pharmaceutical giant Gilead, which has the patent for the drug and is poised to make massive profits. We look at how much drugs like remdesivir will cost, and who can access them, with writer Achal Prabhala, coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa.
Please check back later for full transcript.
Media that fights fascism
Truthout is funded almost entirely by readers — that’s why we can speak truth to power and cut against the mainstream narrative. But independent journalists at Truthout face mounting political repression under Trump.
We rely on your support to survive McCarthyist censorship. Please make a tax-deductible one-time or monthly donation.